GuidelineThe Journal of clinical endocrinology and metabolism2015
Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.
Guideline in The Journal of clinical endocrinology and metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 549 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
549 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Predictors of long-term remission following trans-sphenoidal surgery in cushing's disease: a systematic review and meta-analysis based on different remission criteria.Neurosurgical review · 2026Pooled it
- The effect of hypercortisolism treatment on dyslipidemia in Cushing syndrome: systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- Radiosurgery in recurrent and persistent Cushing's Disease: a Systematic Review and Meta-Analysis.Neurosurgical review · 2026Pooled it
- Paraneoplastic Syndromes in Neuroendocrine Prostate Cancer: A Systematic Review.Current oncology (Toronto, Ont.) · 2024Pooled it
- Trial
- Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment.Diabetes care · 2025Trial
- Prospective study of metyrapone in endogenous Cushing's syndrome (PROMPT).European journal of endocrinology · 2025Trial
- Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease.Journal of endocrinological investigation · 2024Trial
- Long-term cyclic ectopic adrenocorticotropic hormone syndrome with extreme fluctuations and adrenal insufficiency.JCEM case reports · 2026Article
- Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia with ectopic adrenocorticotropic hormone syndrome in Asia.JCEM case reports · 2026Article
- Visualization of relative 11β-hydroxylase (CYP11B1) activity in human cortisol-producing adrenocortical adenoma (CPA) using mass spectrometry imaging-based enzyme histochemistry.Analytical and bioanalytical chemistry · 2026Article
- Hydrogel-based lineage-specific gene therapy prevents recurrence of corticotroph tumors.Molecular therapy. Oncology · 2026Article
- Urinary-free cortisol-based thresholds for differentiating ACTH-dependent Cushing: a Spanish validation study.The Journal of clinical endocrinology and metabolism · 2026Article
- A Case of Carney Complex with Pontine GliomaJournal of clinical research in pediatric endocrinology · 2026Article
- Ectopic ACTH-dependent Cushing syndrome in 3 hospitalized patients: lessons learned from management with osilodrostat.JCEM case reports · 2026Article
- Article
- Racial and ethnic differences in presentation and postoperative recovery after transsphenoidal surgery for cushing disease.Journal of neuro-oncology · 2026Article
- How Common Is Hypercortisolism in Patients With Hypertension? Risk Factors, Epidemiology, and Making a Diagnosis.Diabetes, obesity & metabolism · 2026Review
- Is Hypercortisolism Treatable? Which Patients Should Be Treated and How-A Practical Guide for Clinicians.Diabetes, obesity & metabolism · 2026Review
- The Potential Role of SGLT2 Inhibitors in Cushing's Disease.Diabetes, obesity & metabolism · 2026Review
489 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThe objective is to formulate clinical practice guidelines for treating Cushing's syndrome.
participantsParticipants include an Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. The European Society for Endocrinology co-sponsored the guideline. EVIDENCE: The Task Force used the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews and used the best available evidence from other published systematic reviews and individual studies. CONSENSUS PROCESS: The Task Force achieved consensus through one group meeting, several conference calls, and numerous e-mail communications. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines.
conclusionsTreatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes the normalization of comorbidities via directly treating the cause of Cushing's syndrome and by adjunctive treatments (eg, antihypertensives). Surgical resection of the causal lesion(s) is generally the first-line approach. The choice of second-line treatments, including medication, bilateral adrenalectomy, and radiation therapy (for corticotrope tumors), must be individualized to each patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.